Programs

Programs

Scroll To Explore

Immuno-Oncology

GPCRs constitute strategic targets mediating immunosuppression. The company exploits its expertise in the field to move forward small molecule and antibody based-assets toward the clinic.

 

  • A2aR/A2bR antagonist for immuno-oncology

    Discover
  • EP4R antagonist for immuno-oncology

    Discover
  • Anti-CCR8 monoclonal antibody for immuno-oncology

    Discover
  • First-in-class undisclosed GPCR targeting programs

    Discover

CNS and Rare diseases

With the aim at establishing early partnerships, the company has launched multiple proprietary and collaborative GPCR-based programs in neurology and rare diseases.

 

  • mGluR4/7/8 positive allosteric modulator for Parkinson’s disease

    Discover
  • NPFFR small molecule antagonist to combat the opioid crisis

    Discover
  • Orphan GPCRs for Central Nervous System (CNS) disease area

    Discover
  • PAR2 negative allosteric modulator for rare inflammatory diseases

    Discover
  • MC4R pharmacochaperone for the treatment of early onset obesity

    Discover
  • New GPCRs target identification and validation

    Discover

Participation portfolio

Over the past years, Domain Therapeutics has taken part in the acceleration of breakthrough innovations coming from academia by contributing to their development into dedicated new companies.

 

  • First-in-class CXCR4 agonist to control auto-immune diseases

    Discover
  • Sema3A fusion protein for immuno-oncology

    Discover
  • undisclosed targets

    Discover
Partnerships
Partnering with us